Gossamer Bio, Inc.

GOSS·NasdaqGS·Healthcare
Compare
9.28−0.03 (−0.32%)today
At close: Oct 12, 4:00 PM EDT · May be delayed up to 15 min · USD

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close9.31
Open9.35
Day range8.999.39
52-week range8.99309.60
Off day high−1.17%
Off 52-week high−97.00%
Volume154.84K
Avg. volume (3M)380.38K
Market cap56.76M
EPS (TTM)-52.80
Forward P/E-0.59
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)2.21
Shares outstanding6.12M
Short interest20.53% of float
Earnings dateNov 4, 2026 (est.)
Analyst target82.48
Profit margin−235.00%

Against its peers

Compare in full ›
GOSS GTBP RNTX GANX PASG BDTX
Market cap 56.76M 12.27M 67.71M 68.52M 14.64M 101.42M
P/E (TTM) — — — — — —
Forward P/E -0.6 -0.6 — -2.3 -0.4 -1.8
Price/book -0.6 3.4 6.6 6.0 3.3 1.1
Dividend yield — — — — — —
1-year change −95.23% −63.79% −39.85% −13.68% −57.54% −51.84%
Today −0.32% +1.80% −1.15% −4.27% +23.31% −3.28%

The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.

Latest news

All GOSS news ›
Stock Titan·

Gossamer Bio: D. E. Shaw reports votes on 369,459 shares

Sold shares count toward October meeting voting power at Gossamer Bio (GOSS). Stock Titan - [SCHEDULE 13D/A] Gossamer Bio, Inc. Amended Major Shareholder Report Gossamer Bio: D. E. Shaw reports votes on 369,459 shares Reported voting power…

Stock Titan·

Gossamer Bio grants director option on 10,000 shares

Gossamer Bio (GOSS) is a late-stage clinical biopharmaceutical company developing inhaled seralutinib for pulmonary arterial hypertension and PH-ILD. - [Form 4] Gossamer Bio, Inc. Insider Trading Activity Gossamer Bio grants director…

From articles in the 4Search news index.

In the news

4mentions in 30 days
4with it in the headline
Mixedsentiment

Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 4 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Conservative index. Terms of use.